{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:26:48Z","timestamp":1777577208210,"version":"3.51.4"},"reference-count":278,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1124\/pharmrev.120.000285","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T21:40:14Z","timestamp":1643665214000},"page":"313-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines"],"prefix":"10.1016","volume":"74","author":[{"given":"Simone","family":"Pecetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Kratochvil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaran","family":"Vadivelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000285_bib1","series-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2012"},{"key":"10.1124\/pharmrev.120.000285_bib2","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 variants\u2014clinical, public health, and vaccine implications","volume":"384","author":"Abdool Karim","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.12688\/wellcomeopenres.15927.1","article-title":"Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel","volume":"5","author":"Adams","year":"2020","journal-title":"Wellcome Open Res"},{"key":"10.1124\/pharmrev.120.000285_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib7","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","article-title":"Extremely potent human monoclonal antibodies from COVID-19 convalescent patients","volume":"184","author":"Andreano","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib8","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210281","article-title":"Immunodominant antibody germlines in COVID-19","volume":"218","author":"Andreano","year":"2021","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000285_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","article-title":"SARS-CoV-2 vaccines: lights and shadows","volume":"88","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1124\/pharmrev.120.000285_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1124\/pharmrev.120.000285_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib12","unstructured":"AstraZeneca (Press release, March 25, 2021) AZD1222 US phase III primary analysis confirms safety and efficacy. (http:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html; accessed: September 24, 2021.)"},{"key":"10.1124\/pharmrev.120.000285_bib13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2471\/BLT.20.021220","article-title":"Ensuring equitable access to COVID-19 vaccines","volume":"98","author":"Azevedo Soares","year":"2020","journal-title":"Bull World Health Organ"},{"key":"10.1124\/pharmrev.120.000285_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41467-021-21336-8","article-title":"Discrete SARS-CoV-2 antibody titers track with functional humoral stability","volume":"12","author":"Bartsch","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib21","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41598-021-83108-0","article-title":"Role of IgG against N-protein of SARS-CoV2 in COVID-19 clinical outcomes","volume":"11","author":"Batra","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000285_bib22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib26","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2020.04.022","article-title":"Rational vaccine design in the time of COVID-19","volume":"27","author":"Burton","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1124\/pharmrev.120.000285_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/d41586-021-00268-9","article-title":"Novavax offers first evidence that COVID vaccines protect people against variants","volume":"590","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib30","unstructured":"CanSino (Press release, February 24, 2021) NMPA accepts the application for conditional marketing authorization of CanSinoBIO\u2019s COVID-19 vaccine Convidecia. (http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/651.html; accessed: April 24, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1124\/pharmrev.120.000285_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib33","unstructured":"Celltrion (Press release, March 26, 2021) EMA issues advice on the use of Celltrion\u2019s anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59) for COVID-19 patients in the European Union. (http:\/\/www.celltrionhealthcare.com\/en-us\/board\/newsdetail?modify_key=465&pagenumber=1&keyword=&keyword_type=; accessed: September 24, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/pharmrev.120.000285_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11373-005-9035-9","article-title":"Modular organization of SARS coronavirus nucleocapsid protein","volume":"13","author":"Chang","year":"2006","journal-title":"J Biomed Sci"},{"key":"10.1124\/pharmrev.120.000285_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1124\/pharmrev.120.000285_bib37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000285_bib38","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib39","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib41","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"key":"10.1124\/pharmrev.120.000285_bib43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","article-title":"Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination","volume":"600","author":"Cho","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib45","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib46","unstructured":"Clover (Press release, September 22, 2021) Clover\u2019s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta in global phase 2\/3 SPECTRA trial dominated by variants of concern and interest. (http:\/\/www.cloverbiopharma.com\/news\/83.html; accessed:September 30, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib47","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1126\/science.368.6491.564","article-title":"The race is on for antibodies that stop the new coronavirus","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.372.6539.227","article-title":"The dream vaccine","volume":"372","author":"Cohen","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMe2034495","article-title":"Monoclonal antibodies to disrupt progression of early Covid-19 infection","volume":"384","author":"Cohen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity to SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib51","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib53","doi-asserted-by":"crossref","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/pharmrev.120.000285_bib54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Crotty","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib56","unstructured":"CureVac (Press release, June 16, 2021) CureVac provides update on phase 2b\/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV. (http:\/\/www.curevac.com\/en\/2021\/06\/16\/curevac-provides-update-on-phase-2b-3-trial-of-first- generation-covid-19-vaccine-candidate-cvncov\/; accessed September 24, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib58","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib59","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/pharmrev.120.000285_bib62","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1358\/dot.2008.44.1.1131830","article-title":"Development of subunit vaccines against severe acute respiratory syndrome","volume":"44","author":"Du","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"10.1124\/pharmrev.120.000285_bib64","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.120.000285_bib65","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib67","unstructured":"Faria NR, Claro IM, Candido D, Moyses Franco LA, Andrade PS, Coletti TM, Silva CAM, Sales FC, Manuli ER, Aguiar RS, et al. (2021) Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. (http:\/\/virological.org\/t\/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in- manaus-preliminary-findings\/586)"},{"key":"10.1124\/pharmrev.120.000285_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/infdis\/jiab368","article-title":"SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion","volume":"224","author":"Ferreira","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib70","unstructured":"Food and Drug Administration News Release (Press release, April 16, 2021a) Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. (http:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus- covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody- bamlanivimab; accessed: April 24, 2021.)"},{"key":"10.1124\/pharmrev.120.000285_bib71","unstructured":"Food and Drug Administration (Press release, August 23, 2021b) FDA approves first COVID-19 vaccine. (http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine; accessed: September 30, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib72","unstructured":"Food and Drug Administration (Press release, September 22, 2021c) FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. (http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations; accessed: September 30, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib72a","doi-asserted-by":"crossref","first-page":"eabi4547","DOI":"10.1126\/scitranslmed.abi4547","article-title":"Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates","volume":"13","author":"Francica","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000285_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib74","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib76","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib76a","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","author":"Gebre","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib77","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib78","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib79","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1473-3099(21)00147-X","article-title":"Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study","volume":"21","author":"Goepfert","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib79a","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib80","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib81","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib82","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib83","unstructured":"GSK (Press release, March 10, 2021) Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19. (http:\/\/www.gsk.com\/en-gb\/media\/press-releases\/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19\/; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib84","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.120.000285_bib85","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib86","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","article-title":"Vaccine breakthrough infections with SARS-CoV-2 variants","volume":"384","author":"Hacisuleyman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib88","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1124\/pharmrev.120.000285_bib89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib90","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1038\/s41467-020-18450-4","article-title":"A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib91","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib92","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib93","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","article-title":"Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants","volume":"12","author":"Ikegame","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib94","doi-asserted-by":"crossref","first-page":"eabe5511","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"Isho","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib95","doi-asserted-by":"crossref","first-page":"eabe0367","DOI":"10.1126\/sciimmunol.abe0367","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"Iyer","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib96","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib97","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1182","article-title":"Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"9","author":"Jiang","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"10.1124\/pharmrev.120.000285_bib98a","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000285_bib99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000285_bib101","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(21)00468-2","article-title":"Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection","volume":"397","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib102","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMe2035678","article-title":"(A little) clarity on convalescent plasma for Covid-19","volume":"384","author":"Katz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib103","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib104","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1124\/pharmrev.120.000285_bib105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib107","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diagmicrobio.2017.07.006","article-title":"Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity","volume":"89","author":"Ko","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib108","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2021.05.004","article-title":"Epidemiology and organ specific sequelae of post-acute COVID-19: a narrative review","volume":"83","author":"Korompoki","year":"2021","journal-title":"J Infect"},{"key":"10.1124\/pharmrev.120.000285_bib110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2471\/BLT.20.253591","article-title":"Variant analysis of SARS-CoV-2 genomes","volume":"98","author":"Koyama","year":"2020","journal-title":"Bull World Health Organ"},{"key":"10.1124\/pharmrev.120.000285_bib111","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib112","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib113","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(20)31821-3","article-title":"COVID-19 vaccine trials should seek worthwhile efficacy","volume":"396","author":"Krause","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib114","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1124\/pharmrev.120.000285_bib116","doi-asserted-by":"crossref","first-page":"105038","DOI":"10.1016\/j.meegid.2021.105038","article-title":"Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2","volume":"95","author":"Laiton-Donato","year":"2021","journal-title":"Infect Genet Evol"},{"key":"10.1124\/pharmrev.120.000285_bib117","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib118","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib119","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41586-021-00998-w","article-title":"COVID vaccines and blood clots: five key questions","volume":"592","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1124\/pharmrev.120.000285_bib121","unstructured":"Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, Liu Z, Guo Q, Zou L, Zhang H, et al. (2021) Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. (http:\/\/virological.org\/t\/viral-infection-and-transmission- in-a-large-well-traced-outbreak-caused-by-the-delta-sars-cov-2-variant\/724)"},{"key":"10.1124\/pharmrev.120.000285_bib122","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The Impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib123","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1124\/pharmrev.120.000285_bib124","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","article-title":"Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.120.000285_bib125","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib126","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing activity of BNT162b2-elicited serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib127","doi-asserted-by":"crossref","first-page":"2001112","DOI":"10.1183\/13993003.01112-2020","article-title":"Association between age and clinical characteristics and outcomes of COVID-19","volume":"55","author":"Liu","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1124\/pharmrev.120.000285_bib128","doi-asserted-by":"crossref","first-page":"taab124","DOI":"10.1093\/jtm\/taab124","article-title":"The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus","volume":"28","author":"Liu","year":"2021","journal-title":"J Travel Med"},{"key":"10.1124\/pharmrev.120.000285_bib129","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib131","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib132","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib133","doi-asserted-by":"crossref","first-page":"2000763","DOI":"10.1183\/13993003.00763-2020","article-title":"Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset","volume":"56","author":"Lou","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1124\/pharmrev.120.000285_bib134","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1126\/science.abg8985","article-title":"Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2","volume":"372","author":"Low","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"Lund","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib136","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-021-00352-1","article-title":"A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19","volume":"6","author":"Malherbe","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1124\/pharmrev.120.000285_bib138","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib139","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000285_bib140","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib141","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2021.2088","article-title":"SARS-CoV-2 viral variants\u2014tackling a moving target","volume":"325","author":"Mascola","year":"2021","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000285_bib142","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib143","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib144","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib145","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib146","doi-asserted-by":"crossref","first-page":"109292","DOI":"10.1016\/j.celrep.2021.109292","article-title":"Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7","volume":"35","author":"Meng","year":"2021","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000285_bib147","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib148","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1038\/s41467-021-26672-3","article-title":"Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study","volume":"12","author":"Mizrahi","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib149","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib151","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1124\/pharmrev.120.000285_bib152","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.cell.2021.06.029","article-title":"Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses","volume":"184","author":"Nathan","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib153","unstructured":"Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, Costa A, Duarte D, Pessoa K, and Gon\u00e7alves L (2021) Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the spike protein. (http:\/\/virological.org\/t\/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein\/585)"},{"key":"10.1124\/pharmrev.120.000285_bib154","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib155","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000285_bib156","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41551-020-00611-x","article-title":"Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19","volume":"4","author":"Norman","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1124\/pharmrev.120.000285_bib157","unstructured":"Novavax (Press release, January 28, 2021 Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. (https:\/\/ir.novavax.com\/2021-01-28-Novavax- COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib158","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib159","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib160","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41467-021-21118-2","article-title":"SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity","volume":"12","author":"Ozono","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib161","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study","volume":"507","author":"Padoan","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1124\/pharmrev.120.000285_bib162","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000285_bib163","unstructured":"PANGO (2021) Global report investigating novel coronavirus haplotypes. (http:\/\/cov-lineages.org\/global_report.html; accessed: April 7, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib164","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000285_bib165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/eji.202070035","article-title":"COVID-19: lessons from SARS and MERS","volume":"50","author":"Park","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib166","doi-asserted-by":"crossref","first-page":"110","DOI":"10.12688\/wellcomeopenres.16768.1","article-title":"Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian State of Karnataka","volume":"6","author":"Pattabiraman","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1124\/pharmrev.120.000285_bib167","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","article-title":"The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets","volume":"6","author":"Peacock","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib168","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib169","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib170","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib171","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib172","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib173","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib174","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib176","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib177","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib178","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","article-title":"Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine","volume":"397","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib179","unstructured":"Public Health England (2020) Investigation of novel SARS-COV-2 variant: variant of Concern 202012\/01. (http:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959438\/Technical_Briefing_VOC_SH_NJL2_SH2.pdf; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib180","unstructured":"Public Health England (2021) Investigation of novel SARS-CoV-2 variant: variant of Concern 202012\/01. Technical briefing 5. (http:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959426\/Variant_of_ Concern_VOC_202012_01_Technical_Briefing_5.pdf; accessed on April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib181","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000285_bib182","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib183","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib184","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020368118","article-title":"Vaccinology in the post-COVID-19 era","volume":"118","author":"Rappuoli","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000285_bib185","doi-asserted-by":"crossref","first-page":"108890","DOI":"10.1016\/j.celrep.2021.108890","article-title":"The effect of spike mutations on SARS-CoV-2 neutralization","volume":"34","author":"Rees-Spear","year":"2021","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000285_bib186","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.tips.2020.07.004","article-title":"Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2","volume":"41","author":"Renn","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.120.000285_bib187","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib188","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib189","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib190","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib191","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib192","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib193","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib194","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib195","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1473-3099(21)00216-4","article-title":"CEPI prepares for future pandemics and epidemics","volume":"21","author":"Samarasekera","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib196","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib197","unstructured":"Sanofi (Press release, May 17, 2021) Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial. (http:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-05-17-07-30-00-2230312#; accessed: September 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib198","doi-asserted-by":"crossref","first-page":"613422","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib199","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 immunity from other coronavirus infections","volume":"53","author":"Sariol","year":"2020","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.120.000285_bib200","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.120.000285_bib201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol J"},{"key":"10.1124\/pharmrev.120.000285_bib202","unstructured":"Scientific Pandemic Influenza Group on Modelling Operational subgroup (2021) SPI-M-O: consensus statement on COVID-19. (http:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/993321\/S1267_SPI- M-O_Consensus_Statement.pdf; accessed: September 22, 2021"},{"key":"10.1124\/pharmrev.120.000285_bib203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib204","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41577-020-0389-z","article-title":"Pre-existing immunity to SARS-CoV-2: the knowns and unknowns","volume":"20","author":"Sette","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s12276-021-00604-z","article-title":"On the origin and evolution of SARS-CoV-2","volume":"53","author":"Singh","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1124\/pharmrev.120.000285_bib207","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1124\/pharmrev.120.000285_bib208","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib209","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib211","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","article-title":"Attributes and predictors of long COVID","volume":"27","author":"Sudre","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib212","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/22221751.2020.1770631","article-title":"Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/pharmrev.120.000285_bib213","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib214","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000285_bib215","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib216","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib217","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib218","doi-asserted-by":"crossref","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1124\/pharmrev.120.000285_bib219","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-021-01255-3","article-title":"Sixteen novel lineages of SARS-CoV-2 in South Africa","volume":"27","author":"Tegally","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib221","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2021.08.027","article-title":"The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients","volume":"83","author":"Teyssou","year":"2021","journal-title":"J Infect"},{"key":"10.1124\/pharmrev.120.000285_bib222","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib223","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1016\/j.vaccine.2020.06.026","article-title":"Vaccination against coronaviruses in domestic animals","volume":"38","author":"Tizard","year":"2020","journal-title":"Vaccine"},{"key":"10.1124\/pharmrev.120.000285_bib224","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib225","unstructured":"U.S. Food and Drug Administration (Press release, May 26, 2021) Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19. (http:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus- covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19; accessed: September 24, 2021)."},{"key":"10.1124\/pharmrev.120.000285_bib226","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib227","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib228","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib229","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.abg5268","article-title":"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes","volume":"372","author":"Voss","year":"2021","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib230","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib231","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib232","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib233","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib234","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib235","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib236","doi-asserted-by":"crossref","first-page":"107918","DOI":"10.1016\/j.celrep.2020.107918","article-title":"Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection","volume":"32","author":"Wan","year":"2020","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000285_bib237","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000285_bib238","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib239","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib240","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000285_bib241","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib242","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000285_bib243","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib244","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2020.11.012","article-title":"D614G spike mutation increases SARS CoV-2 susceptibility to neutralization","volume":"29","author":"Weissman","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1124\/pharmrev.120.000285_bib246","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib247","article-title":"First identification of SARS-CoV-2 lambda (C.37) variant in Southern Brazil","author":"Wink","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1124\/pharmrev.120.000285_bib248","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib249","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000285_bib250","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1128\/JCM.43.7.3054-3058.2005","article-title":"Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia","volume":"43","author":"Woo","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1124\/pharmrev.120.000285_bib251","unstructured":"World Health Organization (2020a) Laboratory biosafety guidance related to coronavirus disease (COVID-19). (http:\/\/www.who.int\/publications\/i\/item\/laboratory- biosafety-guidance-related-to-coronavirus-disease-(covid-19); accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib252","unstructured":"World Health Organization (2020b) SARS-CoV-2 mink-associated variant strain\u2014Denmark. (https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2020-DON301; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib253","unstructured":"World Health Organization (2021a) 34th WHO Regulatory Update on COVID-19. (http:\/\/www.who.int\/publications\/m\/item\/34th-who-regulatory-update-on-covid-19; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib254","unstructured":"World Health Organization (2021b) Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). (http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/340920\/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.2-eng.pdf; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib255","unstructured":"World Health Organization (2021c) SARS-CoV-2 Variants. (https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/; accessed January 4, 2022)"},{"key":"10.1124\/pharmrev.120.000285_bib256","unstructured":"World Health Organization (2021d) Technical brief: regulation of COVID-19 vaccines. (http:\/\/www.who.int\/publications\/m\/item\/annex-1st-technical-brief-regulation-of-covid-19-vaccines; accessed: April 24, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib257","unstructured":"World Health Organization (2021e) Vaccine equity. (http:\/\/www.who.int\/campaigns\/vaccine-equity; accessed: September 30, 2021)"},{"key":"10.1124\/pharmrev.120.000285_bib258","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib259","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib260","doi-asserted-by":"crossref","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","article-title":"An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain","volume":"33","author":"Wu","year":"2020","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000285_bib261","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib262","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib263","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000285_bib264","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.120.000285_bib265","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000285_bib266","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000285_bib267","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1124\/pharmrev.120.000285_bib268","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jama.2021.1612","article-title":"Emergence of a novel SARS-CoV-2 variant in Southern California","volume":"325","author":"Zhang","year":"2021","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000285_bib269","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/pharmrev.120.000285_bib270","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","article-title":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice","volume":"84","author":"Zhao","year":"2010","journal-title":"J Virol"},{"key":"10.1124\/pharmrev.120.000285_bib271","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib272","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000285_bib273","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000285_bib274","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400704X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972400704X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:36:59Z","timestamp":1740764219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972400704X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":278,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S003169972400704X"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000285","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s)","name":"copyright","label":"Copyright"}]}}